Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**bioU Uspray** is a Canadian medical-cannabis oral spray product line developed and manufactured by Radient Technologies. It uses proprietary broad-spectrum cannabis extracts and was launched for Medical Cannabis by Shoppers. The product line comprised THC-dominant, CBD-dominant, and balanced THC/CBD formulations, respectively containing 30 mg/mL THC plus 1 mg/mL CBD, 20 mg/mL CBD plus 1 mg/mL THC, or 10 mg/mL THC plus 10 mg/mL CBD. Delta-9-tetrahydrocannabinol primarily mediates cannabinoid-receptor signaling, while cannabidiol has pleiotropic and incompletely defined cannabinoid-system and non-cannabinoid pharmacology. The specific disease indications for bioU Uspray were not stated in the identified public materials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bioU Uspray.